Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method

References

• Organization WHO. 2020. Cancer Today. International Agency for Research on Cancer [cited 2020 Oct 23]. https://gco.iarc.fr/today/home.2018
   Google Scholar
• Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition–Colonoscopic surveillance following adenoma removal. N. Segnan, J.Patnick L vo. K, editor. Endoscopy. 2012; 44 Suppl 3:SE151–63.
   Google Scholar
• NICE Clinical Guideline 27- Referral guidelines for suspected cancer. 2011. www.nice.org.uk/CG027.2011
   Google Scholar
• Hamilton W. Five misconceptions in cancer diagnosis. Br J Gen Pract. 2009;59:441–447.
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of colorectal cancer. Edinburgh: SIGN; 2011. (SIGN publication no. 126). http://www.sign.ac.uk
   Google Scholar
• Vega-Villaamil P, Salve-Bouzo M, Cubiella J, et al. Evaluation of the implementation of Galician Health Service indications and priority levels for colonoscopy in symptomatic patients: prospective, cross-sectional study. Rev Esp Enferm Dig. 2013;105:600–608.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Color Dis. 2012;14:3–17.
   PubMed Web of Science ®Google Scholar
• Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal Cancer: updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Jama. 2016;315:2576.
   PubMed Web of Science ®Google Scholar
• Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–348.
   PubMed Web of Science ®Google Scholar
• Cubiella J, Marzo-Castillejo M, Mascort-Roca JJ, et al. Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update. Gastroenterol Hepatol. 2018;41:585–596.
   PubMed Web of Science ®Google Scholar
• Osborne JM, Wilson C, Moore V, et al. Sample preference for colorectal cancer screening tests: blood or stool? Open J Prev Med. 2012;2:326–331.
   Google Scholar
• Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:1–8.
   PubMed Web of Science ®Google Scholar
• O’Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017;14:169–186.
   PubMed Web of Science ®Google Scholar
• Vega P, Valentín F, Cubiella J. Colorectal cancer diagnosis: pitfalls and opportunities. World J Gastrointest Oncol. 2015;7:422–433.
   PubMed Web of Science ®Google Scholar
• Pin Vieito N, Zarraquiños S, Cubiella J. High-risk symptoms and quantitative faecal immunochemical test accuracy: systematic review and meta-analysis. World J Gastroenterol. 2019;25:2383–2401.
   PubMed Web of Science ®Google Scholar
• Alonso-Abreu I, Alarcón-Fernández O, Gimeno-García AZ, et al. Early Colonoscopy Improves the Outcome of Patients With Symptomatic Colorectal Cancer. Dis Colon Rectum. 2017;60:837–844.
   PubMed Web of Science ®Google Scholar
• Cubiella J, Vega P, Salve M, et al. Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Med. 2016;14:128.
   PubMed Web of Science ®Google Scholar
• Cubiella J, Digby J, Rodríguez-Alonso L, et al. The fecal hemoglobin concentration, age and sex test score: development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. Int J Cancer. 2017;140:2201–2211.
   PubMed Web of Science ®Google Scholar
• Loveday C, Sud A, Jones ME, et al. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Gut. 2020.
   PubMed Web of Science ®Google Scholar
• Zorzi M, Fedeli U, Schievano E, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–790.
   PubMed Web of Science ®Google Scholar
• Levin TR, Corley DA, Jensen CD, et al. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018;155(1383–1391):e5.
   Google Scholar
• Cardoso R, Guo F, Heisser T, et al. Utilisation of colorectal cancer screening tests in european countries by type of screening offer: results from the european health interview survey. Cancers (Basel). 2020;12.
   Web of Science ®Google Scholar
• Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. N Engl J Med. 2012;366:697–706.
   PubMed Web of Science ®Google Scholar
• Quintero E, Carrillo M, Leoz M-L, et al. Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: a Large Multicenter Cross-Sectional Study. PLOS Med. 2016;13:e1002008.
   PubMed Web of Science ®Google Scholar
• Mangas-Sanjuan C, Santana E, Cubiella J, et al. Variation in Colonoscopy Performance Measures According to Procedure Indication. Clin Gastroenterol Hepatol. 2020;18(1216–1223):e2.
   PubMedGoogle Scholar
• Zorzi M, Senore C, Turrin A, et al. Appropriateness of endoscopic surveillance recommendations in organised colorectal cancer screening programmes based on the faecal immunochemical test. Gut. 2016;65:1822–1828.
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Holub J, Eisen G, et al. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc. 2005;62:875–883.
   PubMed Web of Science ®Google Scholar
• Marzo-Castillejo M, Almeda J, Mascort JJ, et al. Appropriateness of colonoscopy requests according to EPAGE-II in the Spanish region of Catalonia. BMC Fam Pract. 2015;16:154.
   PubMed Web of Science ®Google Scholar
• Salas Trejo D Situación actual de los programas de cribado de cáncer colorrectal en España. 2017.
   Google Scholar
• Grady WM, Markowitz SD. The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening. Dig Dis Sci. 2015;60:762–772.
   PubMed Web of Science ®Google Scholar
• Loktionov A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins [Internet]. World J Gastrointest Oncol Baishideng Publishing Group Inc. 2020;124–148.
   Google Scholar
• Worm Ørntoft MB. Review of Blood-Based Colorectal Cancer Screening: how Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation? Clin Colorectal Cancer. 2018;17:e415–e433.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Dominitz JA, Kahi C, et al. Strategies for Colorectal Cancer Screening. Gastroenterology. 2020;158:418–432.
   PubMed Web of Science ®Google Scholar
• Mandel P, Metais P. Les acides nucleiques du plasma sanguine chez l’homme. C R Seances Soc Biol Fil. 1948;142:241–243.
   PubMedGoogle Scholar
• Petit J, Carroll G, Gould T, et al. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: a Systematic Review. J Surg Res. 2019;236:184–197.
   PubMed Web of Science ®Google Scholar
• Vaiselbuh SR. Exosomes in Cancer Research. Cancer Res Front. 2015;1:11–24.
   Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724.
   PubMed Web of Science ®Google Scholar
• M M, S G, G G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11.
   Web of Science ®Google Scholar
• Kamps R, Brandão R, Bosch B, et al. Next-Generation Sequencing in Oncology: genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci. 2017;18:308.
   PubMed Web of Science ®Google Scholar
• Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15:353–365.
   PubMed Web of Science ®Google Scholar
• Glenn TC. Field guide to next-generation DNA sequencers. Mol Ecol Resour. 2011;11:759–769.
   PubMed Web of Science ®Google Scholar
• Huyghe JR, Bien SA, Harrison TA, et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat Genet. 2019;51:76–87.
   PubMed Web of Science ®Google Scholar
• Perkins G, Lu H, Garlan F, et al. Droplet-Based Digital PCR: application in Cancer Research. Adv Clin Chem. 2017;79:43–91.
   PubMed Web of Science ®Google Scholar
• Sealfon SC, Chu TT. RNA and DNA microarrays. Methods Mol Biol. 2011;671:3–34.
   PubMedGoogle Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286–298.
   PubMed Web of Science ®Google Scholar
• Singh MP, Rai S, Suyal S, et al. Genetic and epigenetic markers in colorectal cancer screening: recent advances. Expert Rev Mol Diagn. 2017;17:665–685.
   PubMed Web of Science ®Google Scholar
• Zamani M, Hosseini SV, Mokarram P. Epigenetic biomarkers in colorectal cancer: premises and prospects. Biomarkers. 2018;23:105–114.
   PubMed Web of Science ®Google Scholar
• Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20:109–127.
   PubMed Web of Science ®Google Scholar
• Galanopoulos M, Tsoukalas N, Papanikolaou IS, et al. Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: a review of literature. World J Gastrointest Oncol. 2017;9:142–152.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy N, Spencer E, Torkamani A, et al. Liquid Biopsies for Cancer: coming to a Patient near You. J Clin Med. 2017;6:3.
   Web of Science ®Google Scholar
• Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. Biology (Basel). 2016;5:1–21.
   Google Scholar
• Soozangar N, Sadeghi MR, Jeddi F, et al. Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer. J Cell Physiol. 2018;233:3968–3981.
   PubMed Web of Science ®Google Scholar
• Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics. 2016;8:389–399.
   PubMed Web of Science ®Google Scholar
• Pidsley R, Zotenko E, Peters TJ, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17:208.
   PubMed Web of Science ®Google Scholar
• Š Š, Šálek C, Remešová H. DNA Methylation Validation Methods: a Coherent Review with Practical Comparison. Biol Proced Online. 2019;21:19.
   PubMed Web of Science ®Google Scholar
• Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb Perspect Biol. 2016;8:a019521.
   PubMed Web of Science ®Google Scholar
• Jung G, Hernández-Illán E, Moreira L, et al. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;1–20.
   PubMed Web of Science ®Google Scholar
• Nakato R, Sakata T. Methods for ChIP-seq analysis: a practical workflow and advanced applications. Methods. 2020.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Huang X, Kelleher NL. Epiproteomics: quantitative analysis of histone marks and codes by mass spectrometry. Curr Opin Chem Biol. 2016;33:142–150.
   PubMed Web of Science ®Google Scholar
• Kadali VN, Chandran S, Smitha M. Long Non-Coding RNAs and their “Orchestration” in Cancers. J Appl Biol Biotechnol. 2018;6:57–60.
   Google Scholar
• Kashi K, Henderson L, Bonetti A, et al. Discovery and functional analysis of lncRNAs: methodologies to investigate an uncharacterized transcriptome. Biochim Biophys Acta - Gene Regul Mech. 2016;1859:3–15.
   PubMed Web of Science ®Google Scholar
• Turner AW, Wong D, Khan MD, et al. Multi-Omics Approaches to Study Long Non-coding RNA Function in Atherosclerosis. Front Cardiovasc Med. 2019;6:9.
   PubMed Web of Science ®Google Scholar
• Zhan X, Li B, Zhan X, et al. Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level. Proteomes. 2019;7.
   PubMed Web of Science ®Google Scholar
• Álvarez-Chaver P, De Chiara L, Martínez-Zorzano VS. Proteomic Profiling for Colorectal Cancer Biomarker Discovery. Methods Mol Biol. 2018;1765:241–269.
   PubMedGoogle Scholar
• Álvarez-Chaver P, Otero-Estévez O, de la CMP, et al. Proteomics for discovery of candidate colorectal cancer biomarkers. World J Gastroenterol. 2014;20:3804.
   PubMed Web of Science ®Google Scholar
• Ahn SB, Sharma S, Mohamedali A, et al. Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel. Clin Proteomics. 2019;16:34.
   PubMed Web of Science ®Google Scholar
• Duarte JG, Blackburn JM. Advances in the development of human protein microarrays. Expert Rev Proteomics. 2017;14:627–641.
   PubMed Web of Science ®Google Scholar
• Chauvin A, Boisvert F-M.Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine.Proteomes.2018;6.
   PubMed Web of Science ®Google Scholar
• Cheung PK, Ma MH, Tse HF, et al. The applications of metabolomics in the molecular diagnostics of cancer. Expert Rev Mol Diagn. 2019;19:785–793.
   PubMed Web of Science ®Google Scholar
• Zhou X, Mao J, Ai J, et al. Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics. PLoS One. 2012;7.
   Web of Science ®Google Scholar
• Ni Y, Xie G, Jia W. Metabolomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014;13:3857–3870.
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Yan G, et al. Metabolomics in diagnosis and biomarker discovery of colorectal cancer [Internet]. Cancer Lett Elsevier. 2014;17–20.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang Y, Zhao W, et al. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review. Oncotarget. 2017;8:35460–35472.
   PubMedGoogle Scholar
• Martín-Blázquez A, Díaz C, González-Flores E, et al. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Sci Rep. 2019;9:20198.
   PubMed Web of Science ®Google Scholar
• Williams C, Palviainen M, Reichardt N-C, et al. Metabolomics Applied to the Study of Extracellular Vesicles. Metabolites. 2019;9.
   Web of Science ®Google Scholar
• Palacios‐Ferrer JL, García‐Ortega MB, Gallardo‐Gómez M, et al. Metabolomic profile of cancer stem cell‐derived exosomes from patients with malignant melanoma. Mol Oncol. 2020;1878–0261:12823.
   Google Scholar
• SPIDIA Project. 2020. Standardisation and improvement of generic pre-analytical tools and procedures for in vitro diagnostics. [cited 2020 Dec 9]. https://www.spidia.eu/
   Google Scholar
• Goossens N, Nakagawa S, Sun X, et al. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4:256–269.
   PubMed Web of Science ®Google Scholar
• Poste G, Compton CC, Barker AD. The national biomarker development alliance: confronting the poor productivity of biomarker research and development [Internet]. Expert Rev Mol Diagn. 2015;211–218.
   PubMed Web of Science ®Google Scholar
• Schwarz E. Identification and clinical translation of biomarker signatures: statistical considerations. New York, NY: Methods Mol Biol. Humana Press; 2017. p. 103–114.
   Google Scholar
• Gan X, Wang T, Chen ZY, et al. Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer. Mol Biol Rep. 2020.
   Web of Science ®Google Scholar
• El-Gayar D, El-Abd N, Hassan N, et al. Increased Free Circulating DNA Integrity Index as a Serum Biomarker in Patients with Colorectal Carcinoma. Asian Pacific J Cancer Prev. 2016;17:939–944.
   PubMedGoogle Scholar
• Potter NT, Hurban P, White MN, et al. Validation of a Real-Time PCR-Based Qualitative Assay for the Detection of Methylated SEPT9 DNA in Human Plasma. Clin Chem. 2014;60:1183–1191.
   PubMed Web of Science ®Google Scholar
• He Q, Chen H-Y, Bai E-Q, et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet. 2010;202:1–10.
   PubMedGoogle Scholar
• Bin LB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15:6185–6191.
   PubMed Web of Science ®Google Scholar
• Barták BK, Kalmár A, Péterfia B, et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics. 2017;12:751–763.
   PubMed Web of Science ®Google Scholar
• Nagai Y, Sunami E, Yamamoto Y, et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget. 2017;8:11906–11916.
   PubMed Web of Science ®Google Scholar
• Vychytilova-Faltejskova P, Radova L, Sachlova M, et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis. 2016;37:941–950.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li P, Ju H, et al. Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:2783–2792.
   PubMed Web of Science ®Google Scholar
• Yu W, Wang Z, Shen LI, et al. Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: a meta-analysis. Mol Clin Oncol. 2016;4:237–244.
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhang X, Min M, et al. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:44893–44909.
   PubMedGoogle Scholar
• Basati G, Razavi AE, Pakzad I, et al. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol. 2016;37.
   Google Scholar
• Ng L, Wan TM-H, Man JH-W, et al. Identification of serum miR-139–3p as a non-invasive biomarker for colorectal cancer. Oncotarget. 2017;8:27393–27400.
   PubMedGoogle Scholar
• Shi J, Li X, Zhang F, et al. Circulating lncRNAs associated with occurrence of colorectal cancer progression. Am J Cancer Res. 2015;5:2258–2265.
   PubMed Web of Science ®Google Scholar
• Surinova S, Choi M, Tao S, et al. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med. 2015;7:1166–1178.
   PubMed Web of Science ®Google Scholar
• Croner LJ, Dillon R, Kao A, et al. Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects. Clin Proteomics. 2017;14:28.
   PubMed Web of Science ®Google Scholar
• Dillon R, Croner LJ, Bucci J, et al. Analytical validation of a novel multiplex test for detection of advanced adenoma and colorectal cancer in symptomatic patients. J Pharm Biomed Anal. 2018;154:85–94.
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Weljie AM, Kopciuk KA, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer. 2016;115:848–857.
   PubMed Web of Science ®Google Scholar
• Cavia-Saiz M, Muñiz Rodríguez P, Llorente Ayala B, et al. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Mol Biol Rep. 2014;41:2275–2279.
   PubMed Web of Science ®Google Scholar
• Crotti S, Agnoletto E, Cancemi G, et al. Altered plasma levels of decanoic acid in colorectal cancer as a new diagnostic biomarker. Anal Bioanal Chem. 2016;408:6321–6328.
   PubMed Web of Science ®Google Scholar
• Zhu J, Djukovic D, Deng L, et al. Colorectal Cancer Detection Using Targeted Serum Metabolic Profiling. J Proteome Res. 2014;13:4120–4130.
   PubMed Web of Science ®Google Scholar
• Tan B, Qiu Y, Zou X, et al. Metabonomics Identifies Serum Metabolite Markers of Colorectal Cancer. J Proteome Res. 2013;12:3000–3009.
   PubMed Web of Science ®Google Scholar
• Qi J, Qian C, Shi W, et al. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer. Clin Biochem. 2013;46.
   Web of Science ®Google Scholar
• Hao TB, Shi W, Shen XJ, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111:1482–1489.
   PubMed Web of Science ®Google Scholar
• Danese E, Montagnana M, Minicozzi AM, et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med. 2010;48:1665–1668.
   PubMed Web of Science ®Google Scholar
• Wang J-Y, Hsieh J-S, Chang M-Y, et al. Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers. World J Surg. 2004;28:721–726.
   PubMed Web of Science ®Google Scholar
• Fabbri F, Carloni S, Zoli W, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett. 2013;335:225–231.
   PubMed Web of Science ®Google Scholar
• Lin J-K, Lin P-C, Lin C-H, et al. Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: based on the Mutation Spectra Detected in Primary Tumors. Ann Surg Oncol. 2014;21:680–686.
   PubMed Web of Science ®Google Scholar
• Yang Y-C, Wang D, Jin L, et al. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients. Biosci Rep. 2018;38.
   Web of Science ®Google Scholar
• Wan N, Weinberg D, Liu T-Y, et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. BMC Cancer. 2019;19:832.
   PubMed Web of Science ®Google Scholar
• Chang Y-T, Huang C-S, Yao C-T, et al. Gene expression profile of peripheral blood in colorectal cancer. World J Gastroenterol. 2014;20:14463.
   PubMed Web of Science ®Google Scholar
• Nichita C, Ciarloni L, Monnier-Benoit S, et al. A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer. Aliment Pharmacol Ther. 2014;39:507–517.
   PubMed Web of Science ®Google Scholar
• Xue VW, Cheung MT, Chan PT, et al. Non-invasive Potential Circulating mRNA Markers for Colorectal Adenoma Using Targeted Sequencing. Sci Rep. 2019;9:12943.
   PubMed Web of Science ®Google Scholar
• Lamb YN, Dhillon S. Epi proColon® 2.0 CE: a Blood-Based Screening Test for Colorectal Cancer. Mol Diagnosis Ther. 2017;21:225–232.
   PubMed Web of Science ®Google Scholar
• Nian J, Sun X, Ming S, et al. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: a Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2017;8:e216.
   PubMed Web of Science ®Google Scholar
• Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.
   PubMed Web of Science ®Google Scholar
• Peng J, Qian K, Xin W, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30.
   Web of Science ®Google Scholar
• Song L, Li Y. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years. Biomarker Med. 2017;11:415–418.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen P-M, Liu R-B. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World J Gastrointest Oncol. 2018;10:15–22.
   PubMed Web of Science ®Google Scholar
• Song L, Li Y, Jia J, et al. Algorithm Optimization in Methylation Detection with Multiple RT-qPCR Mills K, editor. PLoS One. 2016;11:e0163333.
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250–281.
   PubMed Web of Science ®Google Scholar
• Danese E, Montagnana M, Lippi G. Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: which is ready for prime time? Ann Transl Med. 2019;7:610.
   PubMed Web of Science ®Google Scholar
• Pedersen SK, Symonds EL, Baker RT, et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015;15:654.
   PubMed Web of Science ®Google Scholar
• Symonds EL, Pedersen SK, Baker RT, et al. A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia. Clin Transl Gastroenterol. 2016;7:e137.
   PubMed Web of Science ®Google Scholar
• Rasmussen SL, Krarup HB, Sunesen KG, et al. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Color Dis. 2016;18:549–561.
   PubMed Web of Science ®Google Scholar
• S J, gaard N, MBW R, et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer- A clinical biomarker discovery and validation study. Clin Epigenetics. 2019;11:1–14.
   PubMed Web of Science ®Google Scholar
• Otero-Estévez O, Gallardo-Gomez M, de la CMP, et al. Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer. Diagnostics (Basel, Switzerland). 2020;10.
   Google Scholar
• Luo H, Zhao Q, Wei W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020;12:1–12.
   Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–126.
   PubMed Web of Science ®Google Scholar
• Liu H-N, Liu -T-T, Wu H, et al. Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods. Cancer Sci. 2018;109:1185–1194.
   PubMed Web of Science ®Google Scholar
• Carter JV, Galbraith NJ, Yang D, et al. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2017;116:762–774.
   PubMed Web of Science ®Google Scholar
• Zheng G, Du L, Yang X, et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer. 2014;111:1985–1992.
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Duran-Sanchon S, Martín AC, et al. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clin Transl Gastroenterol. 2019;10:e00003.
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256:544–551.
   PubMed Web of Science ®Google Scholar
• Shan L, Ji Q, Cheng G, et al. Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer Biomark. 2015;15:47–56.
   PubMed Web of Science ®Google Scholar
• Bahreyni A, Rezaei M, Bahrami A, et al. Diagnostic, prognostic, and therapeutic potency of microRNA 21 in the pathogenesis of colon cancer, current status and prospective. J Cell Physiol. 2019;234:8075–8081.
   PubMed Web of Science ®Google Scholar
• Tsukamoto M, Iinuma H, Yagi T, et al. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer. Oncology. 2017;92:360–370.
   PubMed Web of Science ®Google Scholar
• Baassiri A, Nassar F, Mukherji D, et al. Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer. Int J Mol Sci. 2020;21.
   Web of Science ®Google Scholar
• Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105:849–859.
   PubMedGoogle Scholar
• Uratani R, Toiyama Y, Kitajima T, et al. Diagnostic Potential of Cell-Free and Exosomal MicroRNAs in the Identification of Patients with High-Risk Colorectal Adenomas. PLoS One. 2016;11:e0160722.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Benati M, Danese E, et al. Plasma Expression Levels of Circulating miR-21 are not Useful for Diagnosing and Monitoring Colorectal Cancer. Clin Lab. 2016;62:967–970.
   PubMed Web of Science ®Google Scholar
• Galamb O, Barták BK, Kalmár A, et al. Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol. 2019;25:5026–5048.
   PubMed Web of Science ®Google Scholar
• Barbagallo C, Brex D, Caponnetto A, et al. LncRNA UCA1, Upregulated in CRC Biopsies and Downregulated in Serum Exosomes, Controls mRNA Expression by RNA-RNA Interactions. Mol Ther Nucleic Acids. 2018;12:229–241.
   PubMedGoogle Scholar
• Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016;7:85551–85563.
   PubMed Web of Science ®Google Scholar
• Zhao W, Song M, Zhang J, et al. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. Int J Clin Exp Pathol. 2015;8:14131–14140.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun J, Wang X, et al. A meta-analysis of proteomic blood markers of colorectal cancer. Curr Med Chem. 2020.
   Web of Science ®Google Scholar
• Alnabulsi A, Murray GI. Proteomics for early detection of colorectal cancer: recent updates. Expert Rev Proteomics. 2018;15:55–63.
   PubMed Web of Science ®Google Scholar
• Jones JJ, Wilcox BE, Benz RW, et al. A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016;15(186–194):e13.
   Google Scholar
• Wang H, Li X, Zhou D, et al. Autoantibodies as biomarkers for colorectal cancer: a systematic review, meta-analysis, and bioinformatics analysis. Int J Biol Markers. 2019;34:334–347.
   PubMed Web of Science ®Google Scholar
• Liu S, Tan Q, Song Y, et al. Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: a meta‐analysis. Scand J Immunol. 2020;91.
   Web of Science ®Google Scholar
• Chen H, Werner S, Butt J, et al. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget. 2016;7:16420–16432.
   PubMed Web of Science ®Google Scholar
• Villar-Vázquez R, Padilla G, Fernández-Aceñero MJ, et al. Development of a novel multiplex beads-based assay for autoantibody detection for colorectal cancer diagnosis. Proteomics. 2016;16:1280–1290.
   PubMed Web of Science ®Google Scholar
• Song YF, Xu ZB, Zhu XJ, et al. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer. Clin Transl Oncol. 2017;19:519–524.
   PubMed Web of Science ®Google Scholar
• Bhardwaj M, Weigl K, Tikk K, et al. Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. Mol Oncol. 2020;14:8–21.
   PubMed Web of Science ®Google Scholar
• Gu J, Xiao Y, Shu D, et al. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by 1 H-NMR Spectrometry. Dis Markers. 2019;2019:1–14.
   Web of Science ®Google Scholar
• Ritchie SA, Ahiahonu PW, Jayasinghe D, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010;8:13.
   PubMed Web of Science ®Google Scholar
• Ritchie SA, Tonita J, Alvi R, et al. Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer. 2013;132:355–362.
   PubMed Web of Science ®Google Scholar
• Hata T, Takemasa I, Takahashi H, et al. Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer. Br J Cancer. 2017;117:227–232.
   PubMed Web of Science ®Google Scholar
• Nishiumi S, Kobayashi T, Kawana S, et al. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry. Oncotarget. 2017;8:17115–17126.
   PubMedGoogle Scholar